<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106846</url>
  </required_header>
  <id_info>
    <org_study_id>STU00026695</org_study_id>
    <nct_id>NCT01106846</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of Ketamine in Patients Undergoing Hysteroscopic Endometrial Thermal Ablation Surgery</brief_title>
  <official_title>Analgesic Effect of Ketamine in Patients Undergoing Hysteroscopic Endometrial Thermal Ablation Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: The intraoperative administration of ketamine will result in a 30% reduction in
      opiate requirement following endometrial ablation surgery and the intraoperative
      administration of ketamine will result in a decreased time to meet discharge criteria in the
      PACU following endometrial ablation surgery.

      The research question is &quot;Does intraoperative administration of ketamine result in decreased
      postoperative opiate requirement and time to discharge from the postanesthesia recovery unit
      (PACU) following hysteroscopic endometrial ablation&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperatively:

      Subjects will be recruited up to 21days prior to the day of surgery. After informed consent
      is obtained, subjects will be randomly assigned to one of two groups:

      Group A: Saline group Group B: 1% Ketamine group

      A verbal rating scale (VRS) will be used to assess pain preoperatively. The patient will be
      asked to identify the severity of pain by indicating on a scale of 0-10 where 0 is &quot;no pain&quot;
      and 10 is &quot;the worst pain imaginable&quot;.

      Baseline Quality of Recovery will be obtained. (Appendix F)

      Subjects will be randomized prior to surgery to either Group A or Group B. The randomization
      table is computer generated. There is a 50% allocation to each group.

      Intraoperatively:

      Standard anesthetic monitoring will be used including monitoring of processed EEG including
      either the bi-spectral index (BIS) or similar standard of care ASA monitor. A standardized
      intraoperative anesthetic plan will be utilized by the anesthesia personnel. (Appendix A).
      Study drug will be prepared and labeled in 10mL syringes by research personnel who will not
      be involved in the study assessments. Study drug will be administered on initial insertion of
      Novasure® device (Appendix B).

      Postoperatively:

      Pain scores in the PACU will be assessed using the VRS upon admission and every 30 minutes
      thereafter until discharge criteria are met.

      Additionally, nausea, vomiting and retching episodes will be recorded using a VRS.

      Postoperative analgesic and antiemetic therapy will be standardized and total amounts of
      these agents will be recorded Assessment of psychomimetic effects including sedation and
      agitation will be assess postoperatively prior to discharge using the Richmond
      Agitation/Sedation Scale (Appendix D).

      Acute recovery will be assessed using the Modified Post Anesthesia Discharge Scoring System
      (MPADSS) (Appendix E). A score of 8 or greater will indicate discharge readiness. Time to
      fulfill discharge criteria will be recorded.

      Any other adverse events and medications required will be recorded. These data will be
      recorded by research personnel who will be blinded to the study group assignments.

      Subjects will be contacted by telephone 24 hours after surgery to assess post-discharge
      quality of recovery (Appendix F).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Resources not available to complete.
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery Score Post Operative at 24 Hours</measure>
    <time_frame>24 hours post operative</time_frame>
    <description>Quality of recovery 40 score at 24 hours after the surgical procedure. 40 being a poor recovery and 200 being a good recovery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group A: Saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group A: Saline group , infusion of saline intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: 1% Ketamine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: Infusion of ketamine 1% intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group A: Saline Group</intervention_name>
    <description>Saline continuous infusion</description>
    <arm_group_label>Group A: Saline group</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group B: 1% Ketamine group</intervention_name>
    <description>Administration of 1% ketamine intravenously.</description>
    <arm_group_label>Group B: 1% Ketamine group</arm_group_label>
    <other_name>Ketamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: Female

          -  Age: 18-65 years

          -  Non-pregnant, non-lactating

          -  Surgery: Outpatient hysteroscopic Novasure® endometrial ablation

          -  Language: English speaking

          -  Consent: Obtained

        Exclusion Criteria:

          -  Patient refusal

          -  Under 18 or over age 65

          -  Non-English Speaking

          -  Pregnancy, Breast feeding

          -  Hysteroscopic procedures using Thermachoice® ablation device

          -  Chronic use or addiction to opiates, sedatives, non-opiate analgesics

          -  History of heavy alcohol usage (&gt;4 drinks/day)

          -  Significant cardiovascular or pulmonary disease

          -  Psychiatric or emotional disorder

          -  Allergy to anesthetic agents utilized in the protocol

          -  Glaucoma

          -  Thyrotoxicosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shireen Ahmad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prentice Women's Hosptial</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schenker JG, Margalioth EJ. Intrauterine adhesions: an updated appraisal. Fertil Steril. 1982 May;37(5):593-610. Review.</citation>
    <PMID>6281085</PMID>
  </reference>
  <reference>
    <citation>Jansen FW, Vredevoogd CB, van Ulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TC. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol. 2000 Aug;96(2):266-70.</citation>
    <PMID>10908775</PMID>
  </reference>
  <reference>
    <citation>Wong AY, Wong K, Tang LC. Stepwise pain score analysis of the effect of local lignocaine on outpatient hysteroscopy: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2000 Jun;73(6):1234-7.</citation>
    <PMID>10856489</PMID>
  </reference>
  <reference>
    <citation>Lau WC, Ho RY, Tsang MK, Yuen PM. Patient's acceptance of outpatient hysteroscopy. Gynecol Obstet Invest. 1999;47(3):191-3.</citation>
    <PMID>10087415</PMID>
  </reference>
  <reference>
    <citation>De Iaco P, Marabini A, Stefanetti M, Del Vecchio C, Bovicelli L. Acceptability and pain of outpatient hysteroscopy. J Am Assoc Gynecol Laparosc. 2000 Feb;7(1):71-5.</citation>
    <PMID>10648742</PMID>
  </reference>
  <reference>
    <citation>MacPherson RD, Woods D, Penfold J. Ketamine and midazolam delivered by patient-controlled analgesia in relieving pain associated with burns dressings. Clin J Pain. 2008 Sep;24(7):568-71. doi: 10.1097/AJP.0b013e31816cdb20.</citation>
    <PMID>18716494</PMID>
  </reference>
  <reference>
    <citation>White PF, Way WL, Trevor AJ. Ketamine--its pharmacology and therapeutic uses. Anesthesiology. 1982 Feb;56(2):119-36.</citation>
    <PMID>6892475</PMID>
  </reference>
  <reference>
    <citation>Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998 Jan;88(1):82-8.</citation>
    <PMID>9447860</PMID>
  </reference>
  <reference>
    <citation>Deng XM, Xiao WJ, Luo MP, Tang GZ, Xu KL. The use of midazolam and small-dose ketamine for sedation and analgesia during local anesthesia. Anesth Analg. 2001 Nov;93(5):1174-7.</citation>
    <PMID>11682390</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <results_first_submitted>June 18, 2015</results_first_submitted>
  <results_first_submitted_qc>July 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2015</results_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Shireen Ahmad</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Anesthesia</keyword>
  <keyword>Pain</keyword>
  <keyword>Outpatient surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of recruitment 03/15/2010-02/14/2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Saline Group</title>
          <description>Group A: Saline group , infusion of saline intravenously
Group A: Saline Group: Saline continuous infusion</description>
        </group>
        <group group_id="P2">
          <title>Group B: 1% Ketamine Group</title>
          <description>Group B: Infusion of ketamine 1% intravenously
Group B: 1% Ketamine group: Administration of 1% ketamine intravenously.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Change in surgical procedure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A: Saline Group</title>
          <description>Group A: Saline group , infusion of saline intravenously
Group A: Saline Group: Saline continuous infusion</description>
        </group>
        <group group_id="B2">
          <title>Group B: 1% Ketamine Group</title>
          <description>Group B: Infusion of ketamine 1% intravenously
Group B: 1% Ketamine group: Administration of 1% ketamine intravenously.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.08" spread="3.88"/>
                    <measurement group_id="B2" value="43.12" spread="6.19"/>
                    <measurement group_id="B3" value="44.28" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Recovery Score Post Operative at 24 Hours</title>
        <description>Quality of recovery 40 score at 24 hours after the surgical procedure. 40 being a poor recovery and 200 being a good recovery.</description>
        <time_frame>24 hours post operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Saline Group</title>
            <description>Group A: Saline group , infusion of saline intravenously
Group A: Saline Group: Saline continuous infusion</description>
          </group>
          <group group_id="O2">
            <title>Group B: 1% Ketamine Group</title>
            <description>Group B: Infusion of ketamine 1% intravenously
Group B: 1% Ketamine group: Administration of 1% ketamine intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery Score Post Operative at 24 Hours</title>
          <description>Quality of recovery 40 score at 24 hours after the surgical procedure. 40 being a poor recovery and 200 being a good recovery.</description>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.2" spread="9.15"/>
                    <measurement group_id="O2" value="191.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.947</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Hour post operative</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A: Saline Group</title>
          <description>Group A: Saline group , infusion of saline intravenously
Group A: Saline Group: Saline continuous infusion</description>
        </group>
        <group group_id="E2">
          <title>Group B: 1% Ketamine Group</title>
          <description>Group B: Infusion of ketamine 1% intravenously
Group B: 1% Ketamine group: Administration of 1% ketamine intravenously.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea 60 minutes post operative</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shireen Ahmad, M.D.</name_or_title>
      <organization>Northwestern University</organization>
      <phone>321-472-3585</phone>
      <email>sah704@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

